Addex Therapeutics Ltd (ADXN)
- GlobeNewswire
Addex to Present at Bio€quity Europe 2024
Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain. In his in-person presentation, scheduled for 14:00 – 14:12 CEST, on Monday May 13, 2024 in Room 6 + 7, Mr. Dyer will provide a corporate update and d
- GlobeNewswire
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam. The Pha
- GlobeNewswire
Addex to Present at the Swiss Biotech Day 2024
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland. In his live presentation, scheduled for 13:45 – 14:00 CEST, on April 23, 2024, in the Samarkand room on the third floor, Mr. Dyer will provide a corporat
